On-Demand Webinar: What the New AAPS White Paper Recommends for Immunogenicity Assays Supporting Biosimilars

Presenter: Todd Lester, Associate Director at BioAgilytix

Co-Hosted with: Bioanalysis Zone

The demonstration of similar immunogenicity is a critical requirement for the demonstration of biosimilarity between a biosimilar candidate and the respective reference product. In their webinar, Mr. Lester discusses what the new AAPS White Paper recommends for immunogenicity assays supporting biosimilars., addressing questions such as:

• What are the requirements for immunogenicity assessments of biosimilars?
• Why do the FDA and EMA recommend the use of a single, biosimilar-based assay?
• How are anti-drug antibody (ADA) assays developed and validated for the support of biosimilar drug development programs?

Download Recording


Cell-Based Assays
Learn how BioAgilytix provides the specialized large molecule insight and proven GLP / GMP knowledge needed to support a full range of cell-based assay (CBA) requirements.
SEE OUR CBA EXPERTISE

Pharmacokinetics (PK) Services
See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.
EXPLORE OUR PK SERVICES

Case Studies
Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.
READ OUR CASE STUDIES
Tell Us About Your Project
What are your specific assay needs? Let’s schedule a conversation to review your
questions and requirements with one of our scientists.
SPEAK TO A SCIENTIST